Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Spero Therapeutics (SPRO) Income towards Parent Company (2016 - 2025)

Spero Therapeutics' Income towards Parent Company history spans 10 years, with the latest figure at $31.5 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 301.9% year-over-year to $31.5 million; the TTM value through Dec 2025 reached $8.6 million, up 113.42%, while the annual FY2025 figure was $8.6 million, 113.42% up from the prior year.
  • Income towards Parent Company reached $31.5 million in Q4 2025 per SPRO's latest filing, up from -$7.4 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $52.2 million in Q4 2023 to a low of -$30.1 million in Q1 2022.
  • Average Income towards Parent Company over 5 years is -$7.7 million, with a median of -$13.6 million recorded in 2023.
  • Peak YoY movement for Income towards Parent Company: tumbled 454.02% in 2024, then soared 301.9% in 2025.
  • A 5-year view of Income towards Parent Company shows it stood at -$27.4 million in 2021, then surged by 215.6% to $31.7 million in 2022, then surged by 64.76% to $52.2 million in 2023, then plummeted by 129.89% to -$15.6 million in 2024, then soared by 301.9% to $31.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Income towards Parent Company are $31.5 million (Q4 2025), -$7.4 million (Q3 2025), and -$1.7 million (Q2 2025).